Houston Rx LLC: Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 770
- Recall status
- Ongoing (still active)
- Severity
- Class II: could cause temporary or reversible health problems What recall classes mean
- Where sold
- Nationwide in the USA.
Common questions
- Is Houston Rx Tirzepatide Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL recalled?
- Yes. FDA (drug) recalled Houston Rx Tirzepatide Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL on 2026-10-21. Recall status: Ongoing (still active).
- What is the hazard?
- Lack of assurance of sterility.
- Where was it sold?
- Nationwide in the USA.
Read the official notice at FDA (drug) →
More recalls
- Houston Rx LLC: Sermorelin, 1 mg/mL, 10 ml vial, Sterile injectable solution, RX
- bioQuad Life Sciences: OsteoDenx capsules
- Game Changer Products, LLC: 10 Day Forecast Capsules 3200mg
- Eugia US LLC: Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single
- Trifluent Pharma LLC: Tridacaine III / Lidocaine Patch 5%, 15 envelopes
The text below is copied from the official FDA (drug) record. If anything differs, the official notice is correct.
- Company / brand
- Houston Rx LLC
- Product
- Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
- Reason / hazard
- Lack of assurance of sterility.
- What to do (remedy)
- Classification
- Class II
- Status
- Ongoing
- Distribution / sold at
- Nationwide in the USA.
- Recall initiated
- 2026-09-25
- Code info
- Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.
- Product quantity
- 64 vials
- Voluntary mandated
- Voluntary: Firm initiated
- City
- Houston
- State
- TX
- Country
- United States
- Event id
- 99990
Free daily digest + "My products" watchlist